Celcuity: Overview, Contacts & Employment

About Celcuity

Industry

Biotechnology

Website

celcuity.com

Headquarters

16305 36Th Ave N, Minneapolis, MN 55446, US

Company size

51-200

Celcuity is a clinical-stage, publicly traded biotechnology company focused on extending the lives of cancer patients by developing targeted therapies for multiple solid tumor indications. The company was founded to create a better approach to treating the cellular drivers of tumor growth. Its lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first-in-class PI3K/AKT/mTOR (PAM) pathway inhibitor with a mechanism of action and pharmacokinetic profile that differ significantly from other approved and investigational therapies targeting PI3K or mTOR. Gedatolisib's Phase 3 clinical programs target HR+/HER2- advanced breast cancer in first- and second-line settings, while a Phase 1b/2 trial evaluating it in combination with darolutamide for metastatic castration-resistant prostate cancer is currently ongoing. Headquartered in Minneapolis, Minnesota, Celcuity employs more than 240 people.